New Treatment for Childhood Cancer - Protein May be Key
Synopsis: A protein may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Protein may be key to new treatment in a childhood cancer - Children's Hospital of Philadelphia finds new neuroblastoma target.
Main DigestProtein may be key to new treatment in a childhood cancer - Children's Hospital of Philadelphia finds new neuroblastoma target.
After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.
"Our study implicates this protein as a promising treatment target for high-risk neuroblastoma," said pediatric oncologist Kristina A. Cole, M.D., Ph.D., of the Cancer Center at The Children's Hospital of Philadelphia. "The fact that drugs acting on this protein are already being studied in clinical trials for adult cancers may hasten the process of testing this treatment strategy in children."
Cole is the lead author of a study published online Feb. 2 in the Proceedings of the National Academy of Sciences.
Neuroblastoma, a cancer of the peripheral nervous system, usually appears as a solid tumor in the chest or abdomen. It accounts for 7 percent of all childhood cancers, but because it is often aggressive, it causes 15 percent of all childhood cancer deaths. While low-risk forms of neuroblastoma may spontaneously disappear, in high-risk forms, the cancer tends to return after initial treatment, usually with lethal results.
In the current study, the Children's Hospital researchers performed a comprehensive screen of hundreds of protein kinases encoded by the DNA of neuroblastoma cells. As enzymes, kinases stimulate chemical reactions in the cell, and have been implicated in many cancers as promoting growth and survival of cancer cells. The study team used RNA interference, a powerful research tool that uses small RNA sequences to prevent cells from producing proteins, to interrupt the action of each of the more than 500 kinases made by neuroblastoma tumor cells.
Methodically testing each kinase, one after the other, the researchers identified 30 kinases that, when depleted, caused neuroblastoma cells to die. Among those kinases, cell checkpoint kinase 1 (CHK1) had the strongest effect. "This screen was an unbiased study," said Cole. "We did not know beforehand which kinase would have the most potent effect. In fact, we would not have suspected CHK1, which was thought to be a tumor suppressor. It actually has the opposite effect in neuroblastoma. Its signals appear to drive neuroblastoma growth, likely by allowing them to tolerate stress to DNA caused by the MYC and MCYN oncogenes, which are active in neuroblastoma. Blocking CHK1 activity by RNA interference or by small-molecule inhibitors kills neuroblastoma cells."
When cancer cells are treated with chemotherapy, they can repair themselves though CHK1 signaling, making the chemotherapy less effective. Normal cells have redundant repair pathways and are not affected by CHK1 inhibition. Therefore CHK1 inhibitors are already being tested in adult clinical trials, in combination with chemotherapy, as a possible treatment for lung cancer, pancreatic cancer and other solid tumors. The current study suggests that neuroblastoma cells are particularly sensitive to CHK1 inhibition, without being combined with other agents.
CHK1 is not the first kinase with an important role in neuroblastoma. Some of the collaborators in this study from The Children's Hospital of Philadelphia previously discovered that the anaplastic lymphoma kinase gene (ALK), which carries the code for the ALK kinase, gives rise to some high-risk forms of neuroblastoma. Children's Hospital is currently testing ALK inhibitors in pediatric clinical trials of neuroblastoma, under the sponsorship of the Children's Oncology Group, a cooperative multi-center research organization.
"While it is compelling that there is single-agent activity in neuroblastoma," said Cole. "we anticipate that CHK1 inhibitors combined with chemotherapy will be significantly more potent." Cole expects pediatric oncologists to begin testing CHK1 inhibitors in pediatric clinical trials for neuroblastoma within the next few years.
The National Institutes of Health, the Super-Jake Foundation, the Children's Neuroblastoma Cancer Foundation, the Alex's Lemonade Stand Foundation and the Abramson Family Cancer Research Institute provided financial support for this study. The corresponding author was John M. Maris, M.D., director of the Center for Childhood Cancer Research. All the co-authors are from both Children's Hospital and the University of Pennsylvania School of Medicine.
"RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma," Proceedings of the National Academy of Sciences, Early Edition published online Feb. 2, 2011. doi: 10.1073/pnas.1012351108
About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 460-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit www.chop.edu
📢 Discover Related Topics
👍 Share This Information To:
𝕏.com Facebook Reddit
Page Information, Citing and Disclaimer
Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.
Permalink: <a href="https://www.disabled-world.com/health/cancer/treatment/childhood-neuroblastoma.php">New Treatment for Childhood Cancer - Protein May be Key</a>
Cite This Page (APA): Children's Hospital of Philadelphia. (2011, February 8). New Treatment for Childhood Cancer - Protein May be Key. Disabled World. Retrieved February 22, 2024 from www.disabled-world.com/health/cancer/treatment/childhood-neuroblastoma.php
Disabled World provides general information only. Materials presented are never meant to substitute for qualified professional medical care. Any 3rd party offering or advertising does not constitute an endorsement.